CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage, patient ...
New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients "Seeing these promising results validates our ...
DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Patients with DMD slowly lose muscle ...
Delandistrogene moxeparvovec-rokl showed significant functional benefits in ambulatory DMD patients compared to external controls in the EMBARK trial. The therapy is the only approved gene therapy for ...
Delandistrogene moxeparvovec showed significant long-term stabilization or slowed progression in DMD patients over 3 and 5 years compared to external controls. Clinical trials demonstrated ...
Duchenne muscular dystrophy (DMD) drug Emflaza had a controversial past under its previous owner, but its current captain, PTC Therapeutics, is forging ahead—and a new FDA approval could help. The FDA ...
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its Duchenne muscular dystrophy (DMD) therapy is up to the task. The latest ...
Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non ...
NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback